Lakshmi Sukumaran1, Michael M McNeil2, Pedro L Moro2, Paige W Lewis2, Scott K Winiecki3, Tom T Shimabukuro2. 1. Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention Emory University School of Medicine, Atlanta, Georgia. 2. Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention. 3. Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Abstract
BACKGROUND: Limited data exist on the safety of the measles, mumps, and rubella (MMR) vaccine in adults. We reviewed reports of adverse events (AEs) to the Vaccine Adverse Event Reporting System (VAERS) to assess safety in this previously understudied group. METHODS: VAERS is the national spontaneous vaccine safety surveillance system coadministered by the Centers for Disease Control and Prevention and the US Food and Drug Administration. We searched the VAERS database for US reports of adults aged ≥19 years who received the MMR vaccine from 1 January 2003 to 31 July 2013. We clinically reviewed reports and available medical records for serious AEs, pregnancy reports, and reports for selected prespecified outcomes. RESULTS: During this period, VAERS received 3175 US reports after MMR vaccine in adults. Of these, 168 (5%) were classified as serious, including 7 reports of death. Females accounted for 77% of reports. The most common signs and symptoms for all reports were pyrexia (19%), rash (17%), pain (13%), and arthralgia (13%). We did not detect any new safety findings in empirical Bayesian data mining. We identified 131 reports of MMR vaccine administered to a pregnant woman; the majority of these vaccinations were in the first trimester and in 83 (62%), no AE was reported. CONCLUSIONS: In our review of VAERS data, we did not detect any new or unexpected safety concerns for MMR vaccination in adults. We identified reports of pregnant women exposed to MMR, which is a group in whom the vaccine is contraindicated, suggesting the need for continued provider education on vaccine recommendations and screening.
BACKGROUND: Limited data exist on the safety of the measles, mumps, and rubella (MMR) vaccine in adults. We reviewed reports of adverse events (AEs) to the Vaccine Adverse Event Reporting System (VAERS) to assess safety in this previously understudied group. METHODS: VAERS is the national spontaneous vaccine safety surveillance system coadministered by the Centers for Disease Control and Prevention and the US Food and Drug Administration. We searched the VAERS database for US reports of adults aged ≥19 years who received the MMR vaccine from 1 January 2003 to 31 July 2013. We clinically reviewed reports and available medical records for serious AEs, pregnancy reports, and reports for selected prespecified outcomes. RESULTS: During this period, VAERS received 3175 US reports after MMR vaccine in adults. Of these, 168 (5%) were classified as serious, including 7 reports of death. Females accounted for 77% of reports. The most common signs and symptoms for all reports were pyrexia (19%), rash (17%), pain (13%), and arthralgia (13%). We did not detect any new safety findings in empirical Bayesian data mining. We identified 131 reports of MMR vaccine administered to a pregnant woman; the majority of these vaccinations were in the first trimester and in 83 (62%), no AE was reported. CONCLUSIONS: In our review of VAERS data, we did not detect any new or unexpected safety concerns for MMR vaccination in adults. We identified reports of pregnant women exposed to MMR, which is a group in whom the vaccine is contraindicated, suggesting the need for continued provider education on vaccine recommendations and screening.
Authors: Jens U Rüggeberg; Michael S Gold; José-Maria Bayas; Michael D Blum; Jan Bonhoeffer; Sheila Friedlander; Glacus de Souza Brito; Ulrich Heininger; Babatunde Imoukhuede; Ali Khamesipour; Michel Erlewyn-Lajeunesse; Susana Martin; Mika Mäkelä; Patricia Nell; Vitali Pool; Nick Simpson Journal: Vaccine Date: 2007-03-12 Impact factor: 3.641
Authors: L B Schonberger; D J Bregman; J Z Sullivan-Bolyai; R A Keenlyside; D W Ziegler; H F Retailliau; D L Eddins; J A Bryan Journal: Am J Epidemiol Date: 1979-08 Impact factor: 4.897
Authors: Paul A Gastañaduy; Susan B Redd; Amy Parker Fiebelkorn; Jennifer S Rota; Paul A Rota; William J Bellini; Jane F Seward; Gregory S Wallace Journal: MMWR Morb Mortal Wkly Rep Date: 2014-06-06 Impact factor: 17.586
Authors: Emily P Hyle; Sowmya R Rao; Emily S Jentes; Amy Parker Fiebelkorn; Stefan H F Hagmann; Allison Taylor Walker; Rochelle P Walensky; Edward T Ryan; Regina C LaRocque Journal: Ann Intern Med Date: 2017-05-16 Impact factor: 25.391
Authors: Emily P Hyle; Sowmya R Rao; Audrey C Bangs; Paul Gastañaduy; Amy Parker Fiebelkorn; Stefan H F Hagmann; Allison Taylor Walker; Rochelle P Walensky; Edward T Ryan; Regina C LaRocque Journal: JAMA Pediatr Date: 2020-02-03 Impact factor: 16.193
Authors: Malini DeSilva; Flor M Munoz; Mark Mcmillan; Alison Tse Kawai; Helen Marshall; Kristine K Macartney; Jyoti Joshi; Martina Oneko; Annette Elliott Rose; Helen Dolk; Francesco Trotta; Hans Spiegel; Sylvie Tomczyk; Anju Shrestha; Sonali Kochhar; Elyse O Kharbanda Journal: Vaccine Date: 2016-07-18 Impact factor: 3.641
Authors: Malini DeSilva; Flor M Munoz; Erick Sell; Helen Marshall; Alison Tse Kawai; Alisa Kachikis; Paul Heath; Nicola P Klein; James M Oleske; Fyezah Jehan; Hans Spiegel; Mirjana Nesin; Beckie N Tagbo; Anju Shrestha; Clare L Cutland; Linda O Eckert; Sonali Kochhar; Azucena Bardají Journal: Vaccine Date: 2017-12-04 Impact factor: 3.641